Insulin Glulisine in the Management of Diabetes

Overview

Journal Diabetes Metab Syndr Obes

Publisher Dove Medical Press

Specialty Endocrinology

Date 2011 Mar 26

PMID 21437124

Citations 2

Authors

Satoru Yamada

Affiliations

Soon will be listed here.

Abstract

Insulin glulisine is appealing in principle, but the advantages of this drug over the other rapid-acting insulin analogs are still relatively unknown. The frequency of hypoglycemia, convenience in the timing of administration, and improvements in terms of HbA(1c) seem similar among the rapid-acting insulin analogs, including insulin glulisine. Only properly randomized long-term clinical studies with insulin glulisine will reveal the true value of this novel insulin analog.

Citing Articles

Insulin: evolution of insulin formulations and their application in clinical practice over 100 years.

Bolli G, Cheng A, Owens D Acta Diabetol. 2022; 59(9):1129-1144.

PMID: 35854185 PMC: 9296014. DOI: 10.1007/s00592-022-01938-4.

Uncovering undetected hypoglycemic events.

Unger J Diabetes Metab Syndr Obes. 2012; 5:57-74.

PMID: 22563248 PMC: 3340111. DOI: 10.2147/DMSO.S29367.

References

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

Horvath K, Bock G, Regittnig W, Bodenlenz M, Wutte A, Plank J . Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study. Diabetes Obes Metab. 2007; 10(6):484-91. DOI: 10.1111/j.1463-1326.2007.00734.x. View

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

Becker R . Insulin glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol Ther. 2007; 9(1):109-21. DOI: 10.1089/dia.2006.0035. View

Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven P . Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2008; 360(2):129-39. DOI: 10.1056/NEJMoa0808431. View

Bott U, Ebrahim S, Hirschberger S, Skovlund S . Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes. Diabet Med. 2003; 20(8):626-34. DOI: 10.1046/j.1464-5491.2003.01010.x. View

Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, Narath M . Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2006; (2):CD003287. DOI: 10.1002/14651858.CD003287.pub4. View

Gale E . A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group. Diabet Med. 2000; 17(3):209-14. DOI: 10.1046/j.1464-5491.2000.00258.x. View

Lindholm A, Jensen L, Home P, Raskin P, Boehm B, Rastam J . Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care. 2002; 25(5):876-82. DOI: 10.2337/diacare.25.5.876. View

10.

Ottesen J, Nilsson P, Jami J, Weilguny D, Duhrkop M, Bucchini D . The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia. 1994; 37(12):1178-85. DOI: 10.1007/BF00399790. View

11.

Zimmet P, Alberti K, Shaw J . Global and societal implications of the diabetes epidemic. Nature. 2001; 414(6865):782-7. DOI: 10.1038/414782a. View

12.

Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R . Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care. 1999; 22(5):784-8. DOI: 10.2337/diacare.22.5.784. View

13.

Garg S, Rosenstock J, Ways K . Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine. Endocr Pract. 2005; 11(1):11-7. DOI: 10.4158/EP.11.1.11. View

14.

Maedler K, Donath M . Beta-cells in type 2 diabetes: a loss of function and mass. Horm Res. 2004; 62 Suppl 3:67-73. DOI: 10.1159/000080503. View

15.

Johansson U, Adamson U, Lins P, Wredling R . Improved blood glucose variability, HbA1c insuman Infusat and less insulin requirement in IDDM patients using insulin lispro in CSII. The Swedish Multicenter Lispro Insulin Study. Diabetes Metab. 2000; 26(3):192-6. View

16.

Hoogma R, Schumicki D . Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res. 2006; 38(6):429-33. DOI: 10.1055/s-2006-944549. View

17.

Heise T, Nosek L, Spitzer H, Heinemann L, Niemoller E, Frick A . Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab. 2007; 9(5):746-53. DOI: 10.1111/j.1463-1326.2007.00746.x. View

18.

Gerstein H, Miller M, Byington R, Goff Jr D, Thomas Bigger J, Buse J . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545-59. PMC: 4551392. DOI: 10.1056/NEJMoa0802743. View

19.

Fineberg N, FINEBERG S, Anderson J, Birkett M, Gibson R, Hufferd S . Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes. 1996; 45(12):1750-4. DOI: 10.2337/diab.45.12.1750. View

20.

Ferguson S, Strachan M, Janes J, Frier B . Severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular human insulin. Diabetes Metab Res Rev. 2001; 17(4):285-91. DOI: 10.1002/dmrr.202. View